New Biogen data showed no major safety issues for its Alzheimer's drug — Lilly puts its oncology future in Lox’s hands — Sage Therapeutics depression drug fails phase 3 trial — See more on our front page newsDismiss Notice
TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.Dismiss Notice
Check here for the latest on what's going on at cafepharma. Announcements, new features, etc.